糖尿病周围神经病变与肌少症的关联性

doi:10.6040/j.issn.1671-7554.0.2021.0380

摘要/Abstract

摘要： 目的探讨2型糖尿病患者糖尿病周围神经病变(DPN)与肌少症的关联性。方法选取2型糖尿病患者166例,根据骨骼肌质量指数、握力及步速分为肌少症组(n=62)与非肌少症组(n=104);有DPN的症状或体征、同时存在神经传导速度减慢的患者诊断为DPN。应用单因素分析及多因素Logistic回归分析进行统计学处理,比较两组患者的临床特征、生化指标及DPN患病率的差异。结果肌少症组患者的年龄大于非肌少症组,体质量指数、谷氨酸氨基转移酶水平、骨骼肌质量指数、握力、步速均低于非肌少症组(P<0.05)。肌少症组DPN的比例为83.87%,骨质疏松症比例为70.97%,均高于非肌少症组(P<0.05)。性别为男性(OR=0.025; 95%CI:0.004~0.143)及DPN(OR=32.927, 95%CI:6.169~175.742)为2型糖尿病患者发生肌少症的独立危险因素,而较高的体质指数是2型糖尿病患者发生肌少症的保护性因素(OR=0.546,95%CI:0.420~0.710)。结论 DPN是2型糖尿病患者发生肌少症的独立危险因素,对于患有DPN的患者,应进行肌少症的临床筛查。

关键词: 肌少症, 糖尿病周围神经病变, 2型糖尿病, 骨骼肌质量指数, 体质量指数

Abstract: Objective To investigate the relationship between diabetic peripheral neuropathy(DPN)and sarcopenia in patients with type 2 diabetes mellitus(T2DM). Methods A total of 166 patients with T2DM were selected and divided into sarcopenia group(n=62)and non-sarcopenia group(n=104)according to the skeletal muscle mass index, grip strength and gait speed. Patients with symptoms or signs of DPN and a decrease in nerve conduction were diagnosed as diabetic peripheral neuropathy. Single factor analysis and multivariate Logistic regression analysis were used for statistical processing to compare the differences of clinical characteristics, biochemical indicators and prevalence of diabetic peripheral neuropathy between the two groups. Results The patients in sarcopenia group were older, but the body mass index, alanine aminotransferase level, skeletal muscle mass index, grip strength, and gait speed were lower than those in the non-sarcopenia group(P<0.05). The proportion of DPN and osteoporosis in the sarcopenia group were 83.87% and 70.97%, respectively, which were higher than those in the non-sarcopenia group(P<0.05). Male sex(OR=0.025, 95%CI: 0.004-0.143)and DPN(OR=32.927, 95%CI: 6.169-175.742)were independent risk factors for sarcopenia. Higher body mass index was a protective factor for sarcopenia(OR=0.546, 95%CI: 0.420-0.710). Conclusion DPN is an independent risk factor for sarcopenia in patients with T2DM. For patients with DPN, clinical screening for sarcopenia is recommended.

Key words: Sarcopenia, Diabetic peripheral neuropathy, Type 2 diabetes mellitus, Skeletal muscle mass index, Body mass index

中图分类号:

R589

郑凤杰,宋玉文,孙爱丽,潘喆,王殿辉,娄能俊,吕丽, 庄向华,陈诗鸿. 糖尿病周围神经病变与肌少症的关联性[J]. 山东大学学报 (医学版), 2021, 59(6): 38-44.

ZHENG Fengjie, SONG Yuwen, SUN Aili, PAN Zhe, WANG Dianhui, LOU Nengjun, LYU Li, ZHUANG Xianghua, CHEN Shihong. Correlation between diabetic peripheral neuropathy and sarcopenia[J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 38-44.

参考文献

[1] Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia [J]. J Am Med Dir Assoc, 2011, 12(4): 249-256.
[2] 薛瑜, 王鸥, 邢小平. 肌少症筛查工具[J]. 中华骨质疏松和骨矿盐疾病杂志, 2017, 10(5):483-490. XUE Yu, WANG Ou, XING Xiaoping. Screening tools for sarcopenia [J]. Chinese Journal of Osteoporosis and Bone Mineral Research, 2017, 10(5):483-490.
[3] Wu PY, Huang KS, Chen KM, et al. Exercise, nutrition, and combined exercise and nutrition in older adults with sarcopenia: a systematic review and network meta-analysis[J]. Maturitas, 2021, 145: 38-48. doi: 10.1016/j.maturitas.2020.12.009.
[4] Beaudart C, Sanchez-Rodriguez D, Locquet M, et al. malnutrition as a strong predictor of the onset of sarcopenia [J]. Nutrients, 2019, 11(12):2883
[5] Dhillon RJ, Hasni S. Pathogenesis and management of sarcopenia [J]. Clin Geriatr Med, 2017, 33(1): 17-26.
[6] Albers JW, Pop-Busui R. Diabetic neuropathy: mechanisms, emerging treatments, and subtypes [J]. Curr Neurol Neurosci Rep, 2014, 14(8): 473.
[7] Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation [J]. Diabet Med, 1998, 15(7): 539-553.
[8] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中华糖尿病杂志, 2018, 10(1):64-67. Chinese Diabetes Society. Guidelines for the prevention and control of type 2 diabetes in China(2017 Edition)[J]. Chinese Journal of Diabetes Mellitus, 2018, 10(1):64-67.
[9] Chen LK, Liu LK, Woo J, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia [J]. J Am Med Dir Assoc, 2014, 15(2): 95-101.
[10] 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2017)[J]. 中华骨质疏松和骨矿盐疾病杂志, 2017, 10(5):413-444. Chinese Society of Osteoporosis and Bone Mineral Research. Guidelines for the diagnosis and management of primary osteoporosis(2017)[J]. Chinese Journal of Osteoporosis and Bone Mineral Research,2017, 10(5):413-444.
[11] CruzJentoft AJ, Sayer AA. Sarcopenia[J]. Lancet, 2019, 393(10191): 2636-2646.
[12] Wong R, Wong H, Zhang N, et al. The relationship between sarcopenia and fragility fracture-a systematic review [J]. Osteoporos Int, 2019, 30(3): 541-553.
[13] Ryan AM, Prado CM, Sullivan ES, et al. Effects of weight loss and sarcopenia on response to chemotherapy, quality of life, and survival [J]. Nutrition, 2019, 67-68: 110539. doi: 10.1016/j.nut.2019.06.020.
[14] 郭衍超,王霓雯,姚颖. 老年肌少症的研究进展[J]. 老年医学与保健, 2020, 26(1):4-8.
[15] Kim TN, Park MS, Yang SJ, et al. Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: the Korean Sarcopenic Obesity Study(KSOS)[J]. Diabetes Care, 2010, 33(7): 1497-1499.
[16] Yoon JW, Ha YC, Kim KM, et al. Hyperglycemia is associated with impaired muscle quality in older men with diabetes: the Korean longitudinal study on health and aging [J]. Diabetes Metab J, 2016, 40(2): 140-146.
[17] Tajiri Y, Kato T, Nakayama H, et al. Reduction of skeletal muscle, especially in lower limbs, in Japanese type 2 diabetic patients with insulin resistance and cardiovascular risk factors [J]. Metab Syndr Relat Disord, 2010, 8(2): 137-142.
[18] Andreassen CS, Jakobsen J, Ringgaard S, et al. Accelerated atrophy of lower leg and foot muscles - a follow-up study of long-term diabetic polyneuropathy using magnetic resonance imaging(MRI)[J]. Diabetologia, 2009, 52(6): 1182-1191.
[19] Allen MD, Choi IH, Kimpinski K, et al. Motor unit loss and weakness in association with diabetic neuropathy in humans [J]. Muscle Nerve, 2013, 48(2): 298-300.
[20] Resnick HE, Stansberry KB, Harris TB, et al. Diabetes, peripheral neuropathy, and old age disability [J]. Muscle Nerve, 2002, 25(1): 43-50. doi:10.1016/j.giatpost.2017.07.117.
[21] Scarton A, Jonkers I, Guiotto A, et al. Comparison of lower limb muscle strength between diabetic neuropathic and healthy subjects using OpenSim [J]. Gait Posture, 2017, 58: 194-200. doi:10.1016/j.giatpost.2017.07.117.
[22] Oh TJ, Song Y, Moon JH, et al. Diabetic peripheral neuropathy as a risk factor for sarcopenia [J]. Ann Geriatr Med Res, 2019, 23(4): 170-175.
[23] Mege RM, Goudou D, Giaume C, et al. Is intercellular communication via gap junctions required for myoblast fusion? [J]. Cell Adhes Commun, 1994, 2(4): 329-343.
[24] Schiaffino S, Reggiani C. Molecular diversity of myofibrillar proteins: gene regulation and functional significance [J]. Physiol Rev, 1996, 76(2): 371-423.
[25] Allen MD, Kimpinski K, Doherty TJ, et al. Length dependent loss of motor axons and altered motor unit properties in human diabetic polyneuropathy [J]. Clin Neurophysiol, 2014, 125(4): 836-843.
[26] Allen MD, Major B, Kimpinski K, et al. Skeletal muscle morphology and contractile function in relation to muscle denervation in diabetic neuropathy [J]. J Appl Physiol(1985), 2014, 116(5): 545-552.
[27] Langer HT, Afzal S, Kempa S, et al. Nerve damage induced skeletal muscle atrophy is associated with increased accumulation of intramuscular glucose and polyol pathway intermediates [J]. Sci Rep, 2020, 10(1): 1908.
[28] Bohnert KL, Hastings MK, Sinacore DR, et al. Skeletal muscle regeneration in advanced diabetic peripheral neuropathy [J]. Foot Ankle Int, 2020, 41(5): 536-548.
[29] Toosizadeh N, Mohler J, Armstrong DG, et al. The influence of diabetic peripheral neuropathy on local postural muscle and central sensory feedback balance control [J]. PLoS One, 2015, 10(8): e135255. doi: 10.1371/journal.pone.0135255.
[30] Bonewald LF, Kiel DP, Clemens TL, et al. Forum on bone and skeletal muscle interactions: summary of the proceedings of an ASBMR workshop [J]. J Bone Miner Res, 2013, 28(9): 1857-1865.
[31] Chen Q, Zeng J, Chen Y, et al. Efficacy of Xianling Gubao capsule in treating sarco-osteopenia: Protocol for a systematic review and meta-analysis [J]. Medicine(Baltimore), 2019, 98(20): e15672. doi: 10.1097/MD.0000000000015672.
[32] Verschueren S, Gielen E, ONeill TW, et al. Sarcopenia and its relationship with bone mineral density in middle-aged and elderly European men [J]. Osteoporos Int, 2013, 24(1): 87-98.
[33] 帅波, 沈霖, 杨艳萍, 等. 武汉地区中老年男性肌肉减少症与骨密度的相关性[J]. 中华骨质疏松和骨矿盐疾病杂志, 2016, 9(3):257-263. SHUAI Bo, SHEN Lin, YANG Yanping, et al. Relationship between sarcopenia and bone mineral density in middle-aged and elderly men in Wuhan area [J]. Chinese Journal of Osteoporosis and Bone Mineral Research, 2016, 9(3):257-263.
[34] Tagliaferri C, Wittrant Y, Davicco MJ, et al. Muscle and bone, two interconnected tissues [J]. Ageing Res Rev, 2015, 21: 55-70. doi: 10.1016/j.arr.2015.03.002.
[35] Cederholm T, Cruz-Jentoft AJ, Maggi S. Sarcopenia and fragility fractures [J]. Eur J Phys Rehabil Med, 2013, 49(1): 111-117.
[36] 张栌尹,莫永珍,欧阳晓俊,等. 住院老年患者肌少症患病率及相关因素分析[J]. 老年医学与保健, 2021, 27(1): 64-67. ZHANG Luyin, MO Yongzhen, OUYANG Xiaojun, et al. Analysis of prevalence and related factors of sarcopenia in hospitalized elderly patients[J]. Geriatrics & Health Care, 2021, 27(1): 64-67.
[37] Rong Y, Bian A, Hu H, et al. Study on relationship between elderly sarcopenia and inflammatory cytokine IL-6, anti-inflammatory cytokine IL-10 [J]. BMC Geriatrics, 2018, 18(1):308..
[38] Moon JS, Yoon JS, Won KC, et al. The role of skeletal muscle in development of nonalcoholic Fatty liver disease [J]. Diabetes Metab J, 2013, 37(4): 278-285.
[39] Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People [J]. Age Ageing, 2010, 39(4): 412-423.
[40] Papadopoulou SK. Sarcopenia: a contemporary health problem among older adult populations [J]. Nutrients, 2020, 12(5):1293.
[41] Verschueren S, Gielen E, ONeill TW, et al. Sarcopenia and its relationship with bone mineral density in middle-aged and elderly European men [J]. Osteoporos Int, 2013, 24(1): 87-98.
[42] Vespasiani-Gentilucci U, De Vincentis A, Ferrucci L, et al. Low Alanine aminotransferase levels in the elderly population: frailty, disability, sarcopenia, and teduced survival [J]. J Gerontol A Biol Sci Med Sci, 2018, 73(7): 925-930.
[43] Chung SM, Moon JS, Yoon JS, et al. Low alanine aminotransferase levels predict low muscle strength in older patients with diabetes: a nationwide cross-sectional study in Kore a[J]. Geriatr Gerontol Int, 2020, 20(4): 271-276.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed